As immunotherapy companies pivot into autoimmune disease, a transformative era of immune reset is entering early rounds of clinical trials, while tolerance strategies continue into later trials to deliver safe, effective, and commercially viable tolerization therapeutics.

Beacon Targeted Therapies Trials database cites 62 clinical trials with CAR-T therapy and 47 with cell engager antibodies recruiting or active in autoimmune disease in 2024.

How can companies go from single candidate to clinical batch in set time frames, understand the risk being taken on to get there as fast as possible or navigate the possibility of future basket trials as the modularity of autoimmune targets enables multiple patient groups to be treated?

The Autoimmunity Pharma & Biotech Partnering Summit fits in the perfect niche to support multiple modalities to successfully advance candidate development from early discovery through to clinical proof-of-concept via partnerships. Their next decisions are how to propel their joint efforts through clinical development to approval, and for this, they are lining up service providers of choice.

In 2025, position your trusted expertise with biotech decision-makers embarking on the next big thing, to gain your market share early and validate your expertise to grow the next million-dollar therapies in autoimmune disease.